Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Director Sells $131,900.00 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Director Saira Ramasastry sold 10,000 shares of the stock in a transaction on Friday, June 21st. The shares were sold at an average price of $13.19, for a total value of $131,900.00. Following the transaction, the director now directly owns 40,485 shares in the company, valued at $533,997.15. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Day One Biopharmaceuticals Stock Performance

NASDAQ:DAWN opened at $13.68 on Monday. Day One Biopharmaceuticals, Inc. has a one year low of $9.67 and a one year high of $18.07. The business has a fifty day moving average price of $14.68 and a 200-day moving average price of $14.74.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Monday, May 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). Equities research analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.69 EPS for the current year.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC increased its stake in Day One Biopharmaceuticals by 19.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,032,384 shares of the company’s stock worth $33,575,000 after buying an additional 336,281 shares in the last quarter. Bayesian Capital Management LP purchased a new stake in Day One Biopharmaceuticals in the 1st quarter worth $221,000. Estuary Capital Management LP increased its stake in Day One Biopharmaceuticals by 82.5% in the 1st quarter. Estuary Capital Management LP now owns 1,611,137 shares of the company’s stock worth $26,616,000 after buying an additional 728,240 shares in the last quarter. Altitude Crest Partners Inc. bought a new position in shares of Day One Biopharmaceuticals during the 1st quarter valued at about $3,230,000. Finally, Summit Rock Advisors LP bought a new stake in shares of Day One Biopharmaceuticals in the first quarter worth about $851,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on DAWN. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday. JPMorgan Chase & Co. increased their price target on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a report on Monday, April 22nd. Needham & Company LLC restated a “buy” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Wednesday, June 19th. Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. Finally, Piper Sandler restated an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $37.67.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.